Simvastatin enhances the efficacy of Bcr-Abl tyrosine kinase inhibitor nilotinib in chronic myeloid leukemia.
One of the major challenges in treatment of chronic myeloid leukemia (CML) is the continual emergence of new resistance to single agent Bcr-Abl tyrosine kinase inhibitors (TKIs). A strategy to cope with cancer progression is by targeting multiple levels of signaling pathways downstream of B...
| Main Author: | |
|---|---|
| Other Authors: | |
| Format: | Final Year Project (FYP) |
| Language: | English |
| Published: |
2011
|
| Subjects: | |
| Online Access: | http://hdl.handle.net/10356/45121 |